| Title |
Evaluation of atrial fibrillation management and cardiovascular risk profile in atrial fibrillation patients: A cross-sectional survey / |
| Authors |
Račkauskas, Gediminas ; Zabiela, Vytautas ; Marinskis, Germanas ; Baranauskas, Arvydas ; Balkutė, Deimilė ; Alunderytė, Justina ; Puodžiukynas, Aras ; Kazakevičius, Tomas ; Kviesulaitis, Vilius ; Aidietis, Audrius |
| DOI |
10.1016/j.medici.2017.01.005 |
| Full Text |
|
| Is Part of |
Medicina.. Wrocław : Elsevier. 2017, vol. 53, no. 1, p. 19-25.. ISSN 1010-660X. eISSN 1648-9144 |
| Keywords [eng] |
Atrial fibrillation ; Anticoagulants ; Risk factors ; Cross-sectional studies ; Lithuania |
| Abstract [eng] |
Objective The aim of this study to investigate the most frequent risk factors of atrial fibrillation (AF), co-morbidities, complications associated with AF and the use of anticoagulants and other medications in patients who were referred to university hospitals in Lithuania. Materials and methods This cross-sectional study enrolled consecutive inpatients and outpatients with AF presenting to cardiologists in the two biggest Lithuanian university hospitals from November 2013 to May 2014. AF diagnosis was confirmed by a 12-lead ECG or 24-h Holter with an episode duration of >30 s. Results A total number of 575 patients were recruited, and complete data on clinical subtype were available for 515 patients (mean age of 70.7 years; 48.5% of women). Permanent AF was the most frequent type of AF (46.6%). Common comorbidities were hypertension (85.8%), heart failure (77.9%) and coronary artery disease (51.8%). Amiodarone was the most common antiarrhythmic agent used in 14.6% of the patients, while beta-blockers and digoxin were the most often used rate control drugs (59.6% and 10.7%, respectively). Oral anticoagulants were used by 53.3% of the patients; of them, 95.6% used vitamin K antagonists, while non-vitamin K antagonist were used by only 4.4%. The INR within a therapeutic range (2.0–3.0) was documented in 19.2% of the patients. Other antithrombotic drugs such as aspirin and clopidogrel were used in 13.7% and 2.0% of the patients, respectively; dual antiplatelet treatment was administered in 6.2% of the patients. Of the entire cohort, the mean CHA2DS2-VASc score was 3.97 ± 1.6 and the mean HAS-BLED score was 2.25 ± 1.0. Conclusions Compliance with the treatment guidelines remains suboptimal and further patient education is needed. |
| Published |
Wrocław : Elsevier |
| Type |
Journal article |
| Language |
English |
| Publication date |
2017 |
